DANAHER CORP (DHR) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:DHR - US2358511028 - Common Stock
DHR Key Statistics, Chart & Performance
The current stock price of DHR is 238.37 USD. In the past month the price increased by 3.45%. In the past year, price increased by 1.4%.
DHR Latest News, Press Relases and Analysis
DHR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.63 | 232.51B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 200.78 | 61.01B | ||
| IQV | IQVIA HOLDINGS INC | 20.84 | 41.28B | ||
| A | AGILENT TECHNOLOGIES INC | 26.62 | 42.11B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.5 | 30.34B | ||
| WAT | WATERS CORP | 31.24 | 23.62B | ||
| ILMN | ILLUMINA INC | 32.36 | 21.56B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.97 | 19.82B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.61 | 16.76B | ||
| TEM | TEMPUS AI INC | N/A | 11.79B | ||
| RVTY | REVVITY INC | 21.8 | 11.84B | ||
| CRL | CHARLES RIVER LABORATORIES | 20.94 | 10.87B |
Related stock screener links
About DHR
Company Profile
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 61,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Company Info
DANAHER CORP
2200 Pennsylvania Ave NW Ste 800W
WASHINGTON WASHINGTON DC 20037 US
CEO: Rainer M. Blair
Employees: 62000
Phone: 12028280850
DANAHER CORP / DHR FAQ
What does DHR do?
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 61,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
What is the current price of DHR stock?
The current stock price of DHR is 238.37 USD. The price increased by 1.43% in the last trading session.
Does DHR stock pay dividends?
DANAHER CORP (DHR) has a dividend yield of 0.54%. The yearly dividend amount is currently 1.05.
How is the ChartMill rating for DANAHER CORP?
DHR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for DHR stock?
The PE ratio for DANAHER CORP (DHR) is 30.92. This is based on the reported non-GAAP earnings per share of 7.71 and the current share price of 238.37 USD.
Is DANAHER CORP (DHR) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DHR.
What is the outstanding short interest for DANAHER CORP?
The outstanding short interest for DANAHER CORP (DHR) is 1.38% of its float.
DHR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DHR. When comparing the yearly performance of all stocks, DHR turns out to be only a medium performer in the overall market: it outperformed 60.21% of all stocks.
DHR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DHR. While DHR has a great profitability rating, there are some minor concerns on its financial health.
DHR Financial Highlights
Over the last trailing twelve months DHR reported a non-GAAP Earnings per Share(EPS) of 7.71. The EPS increased by 3.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.43% | ||
| ROA | 4.38% | ||
| ROE | 6.86% | ||
| Debt/Equity | 0.33 |
DHR Forecast & Estimates
31 analysts have analysed DHR and the average price target is 263.26 USD. This implies a price increase of 10.44% is expected in the next year compared to the current price of 238.37.
For the next year, analysts expect an EPS growth of 4.04% and a revenue growth 3.14% for DHR